The impact of standard accelerated stability conditions on antibody higher order structure as assessed by mass spectrometry

Richard A. Kerr, David A. Keire, and Hongping Ye

Division of Pharmaceutical Analysis, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, St. Louis, USA

ABSTRACT

Protein therapeutic higher order structure (HOS) is a quality attribute that can be assessed to help predict shelf life. To model product shelf-life values, possible sample-dependent pathways of degradation that may affect drug efficacy or safety need to be evaluated. As changes in drug thermal stability over time can be correlated with an increased risk of HOS perturbations, the effect of long-term storage on the product should be measured as a function of temperature. Here, complementary high-resolution mass spectrometry methods for HOS analysis were used to identify storage-dependent changes of biotherapeutics (bevacizumab (Avastin), trastuzumab (Herceptin), rituximab (Rituxan), and the NIST reference material 8671 (NISTmAb)) under accelerated or manufacturer-recommended storage conditions. Collision-induced unfolding ion mobility-mass spectrometry data showed changes in monoclonal antibody folded stability profiles that were consistent with the appearance of a characteristic unfolded population. Orthogonal hydrogen-deuterium exchange-mass spectrometry data revealed that the observed changes in unfolding occurred in parallel to changes in HOS localized to the periphery of the hinge region. Using intact reverse-phase liquid chromatography-mass spectrometry, we identified several mass species indicative of peptide backbone hydrolysis, located between the variable and constant domains of the heavy chain of bevacizumab. Taken together, our data highlighted the capability of these approaches to identify age- or temperature-dependent changes in biotherapeutic HOS.

Introduction

The reported shelf-life of a therapeutic product is generally calculated using data from several sources and combined with statistical modelling to estimate the duration over which a product is expected to retain therapeutic efficacy, purity and safety. To correctly model these shelf-lives, several quality attributes (QAs) are identified through quality risk management and experimentation, which may include any physical, chemical or biological properties/characteristics. In the US, shelf-life assessment is often performed using a Quality by Design approach that ensures that the knowledge base accounts for the association between the clinical properties and selected QAs of a product, while further accounting for how variations in the manufacturing process may affect the QAs and clinical properties.

Given that process-related changes in these QAs are to be expected during the biotherapeutic production cycle, substantial efforts have been made to identify any attribute that may affect the stability, safety or efficacy of the product. Notable product QAs include, but are not limited to, formulation, impurity-dependent fragmentation/proteolysis, glycan profile and oxygen- or light-dependent protein modifications. Additionally, the cellular systems, such as Chinese hamster ovary cells, used to express these biotherapeutics can cause variations in the active pharmaceutical ingredient QAs between production batches. Subvisible protein aggregates, given their known association with immune-mediated responses, are a QA with direct safety-related concerns. Several manufacturer-dependent factors known to enhance the risk of forming these subvisible aggregates include, but are not limited to, filtration, agitation, freeze-thaw and lyophilization. Because unfolding of the higher order structure (HOS) of monoclonal antibodies (mAbs) provides a pathway for aggregates to form, the effect of mAb thermal stability as a function of time on the formulated products needs to be evaluated. While higher temperatures lead to a greater risk of unfolding within proteins, including transient unfolding events, reduced thermal stability will further enhance the risk of potential protein denaturation, misfolding and aggregation.

Substantial efforts have been made by the manufacturers during product development and manufacture cycles to identify the consequences of long-term storage on the stability and safety of the products through the optimization of accessible storage and formulation conditions, using real-time/real-temperature data supported by the use of forced degradation studies. While ICH guidelines recommend that the expiration date only be calculated based on these real-time and real-condition datasets, accelerated storage studies are still considered extremely valuable despite the non-Arrhenius degradation behaviors associated with their use.
Notably, accelerated storage studies represent an important approach for analytical method validation, in addition to the preliminary assessment of manufacturing process changes, such as scale-up and/or formulation changes. Product formulation considerations known to affect the long-term stability of biotherapeutic products include both the concentration and type of non-ionic detergent used (e.g., Polysorbate 20 vs Polysorbate 80). Notable work by Singh and co-workers, using a variety of analytical methods, indicated that both Polysorbate 20 and Polysorbate 80 exhibited a high affinity for the mAb N-terminal variable (\(V_1/V_L\)) and constant (\(C_1/C_L\)) containing antigen-binding fragment (Fab) domain compared to the C-terminal Fc domains. Compared to Polysorbate 20, Polysorbate 80 was shown to exhibit a higher affinity for the Fab domain, and as a consequence may, provide enhanced levels of protection against tertiary structure perturbations within this region of the mAb.

Consistent with above concerns regarding long-term thermal stability on biotherapeutic HOS, we investigated the consequences of accelerated storage conditions (6 months at 25 ± 2°C, 60 ± 5% RH (relative humidity)) on four commercially available mAbs, bevacizumab (Avastin), trastuzumab (Herceptin), rituximab (Rituxan), and the NIST reference material 8671 (NISTmAb). To provide additional sample comparison data, two different lots of rituximab were studied, including an in-date (unexpired) lot and an out-of-date (expired) lot with an expiration date several years before the start of the study, which was used as a negative control. Each of these biotherapeutic products exhibits variations in terms of their formulations (Table 1) and sequences (Table 2). To compare the effect of accelerated storage on the HOS of these products, four different mass spectrometric methods, including native ion mobility-mass spectrometry (IM-MS), collision-induced unfolding (CIU), hydrogen-deuterium exchange-mass spectrometry (HDX-MS), and intact protein reverse-phase-liquid chromatography-mass spectrometry (RP-LC-MS), were used for analysis, each providing a complementary dataset.

### Results

**Native ion mobility-mass spectrometry and collision-induced unfolding of biotherapeutics subjected to accelerated storage conditions**

The effects of accelerated storage conditions on the native-like folded protein structure of the biotherapeutics included in this study were examined with gas-phase travelling-wave collision cross sections measured in Nitrogen (\(^{13}\text{N}_2\)) measurements using native IM-MS. With optimized instrumental parameters, native IM-MS methods are generally accepted to provide biologically relevant measurements of the rotationally averaged solution phase structure. Several relevant review articles provide comprehensive information on IM-MS.

Calculated \(^{13}\text{N}_2\) CCS values comparing the selected biotherapeutics before and after incubating for six months at the accelerated storage conditions (25 ± 2°C with 60 ± 5% RH) stipulated

### Table 1. Product formulations of mAbs studied.

| Non-proprietary name | Bevacizumab (Avastin) | Trastuzumab (Herceptin) | NISTmAb RM8671 | Rituximab (Rituxan) |
|----------------------|----------------------|------------------------|-----------------|-------------------|
| **Brand-name**       |                      |                        |                 |                   |
| **Concentration**    | 25 mg/ml             | 21 mg/ml               | 10 mg/ml        | 10 mg/ml          |
| **Storage state**    | Liquid (2–8°C)       | Lyophilized powder (2–8°C) | Frozen Liquid (–80°C) | Liquid (2–8°C) |
| **Non-ionic detergent** | 0.4 mg/ml Polysorbate 20 | 0.1 mg/ml Polysorbate 20 | /               | /                |
| **α,α-trehalose dihydrate** | 60 mg/ml           | 19.1 mg/ml             | /               | /                |
| **Buffer Salt 1**    | 5.8 mg/ml Sodium phosphate monobasic monohydrate | 0.3 mg/ml L-Histidine | 1.9 mg/ml L-Histidine | 7.4 mg/ml Sodium citrate dihydrate |
| **Buffer Salt 2**    | 1.2 mg/ml Sodium phosphate dibasic anhydrous HCl | 0.5 mg/ml L-Histidine HCl | 2.4 mg/ml L-Histidine HCl | 9 mg/ml Sodium Chloride |
| **Formulated pH**    | 6.2                  | 6                      | 6               | 6.5               |

* Reported concentrations represent the final product formulation, at the point of use, accounting for any required reconstitution steps.
** Storage conditions are the reported, manufacturer recommended storage conditions.
*** α,α-trehalose dihydrate represents a commonly used bioprotectant.
by the International Council for Harmonisation (ICH) are presented in Figure 1; additional data is provided in supporting information (SI) Table 1. Across all samples studied, the $^{15}$N CCS$_{N2}$ values were consistent with previously published theoretical cross section values using the trajectory method. However, these data were not consistent with previously published data that inferred a degree of gas phase structural compactness occurring. Therefore, accounting for the errors presented, no change in the rotationally averaged structure of the mAbs studied was observed after the 6-months incubation period at the stated accelerated storage conditions.

These data suggest that either there is no change in rotationally averaged mAb structure, or highly localized minor structural variations in HOS may be too subtle to resolve using cross-sectional analysis given the lower spatial resolution of the measurement. Thus, orthogonal approaches were applied to examine the impact of accelerated storage conditions on the structural stability of the mAbs studied.

In tandem with the above native IM-MS studies, we further leveraged the power of CIU, which is considered an orthogonal measurement to differential scanning calorimetry, to measure differences in the gas phase stability of the chosen biotherapeutics before and after sample incubation. CIU leverages the capability of IM-MS to measure changes in structural conformation as a function of gas-phase collisional activation. Changes in the structural stability of the gas phase ions can then be quantified against reference datasets using difference plots and scaled deviation score (SDS) values.

Data comparing the stability of a control against mAbs subjected to accelerated aging conditions (6 months) are presented in Figure 2, with additional data presented in SI Figures 1 and 2. These data demonstrated that, as a consequence of the storage conditions used, changes in biotherapeutic structural stability were readily observed by CIU-IM-MS. These changes were especially pronounced for the unexpired lots (bevacizumab, trastuzumab, NISTmAb and in-date rituximab), after incubating at the 6-month accelerated storage conditions, with localized SDS unfolding differences all exceeding 300 at 1.44 keV (lab frame energy) compared to the baseline at 0.5 keV (Figure 2d). These observations were further supported by greatly increased root-mean-square deviation (RMSD) difference plot scores (>6%), indicative of these changes in unfolding (Figure 2c). Consistent with these observations, excluding the expired rituximab lot that showed no difference, samples stored under the manufacturer-recommended conditions (2–8°C) retained these reproducible changes in unfolding (SI Figure 1). However, compared to lots incubated at the ICH-stipulated accelerated storage conditions, samples incubated at the manufacturer-recommended conditions exhibited smaller changes in SDS intensity (≤200, SI Figure 1) at 1.44 keV.

Compared to the unexpired sample lots (bevacizumab, trastuzumab, NISTmAb and in-date rituximab), the expired rituximab lot exhibited smaller changes in SDS intensity under the accelerated storage conditions ($183.6 \pm 28.6$ at 1.44 keV) (Figure 2d). No changes were observed for those samples that were stored under the manufacturer-recommended conditions (2–8°C, SI Figure 1d). These observations are further supported by minimal changes in the global unfolding profile, by difference plot analysis with RMSD values ≤3.06% (Figure 2c, and SI Figure 1c).

Closer inspection of the data presented above revealed that the most pronounced changes in SDS, at 1.44 keV (Figure 2d), occurred in tandem with the emergence of a new structural unfolding species identified here as ‘x’. Importantly, this pronounced change in the SDS was found to be consistent across all samples studied (bevacizumab, trastuzumab, NISTmAb, in-date and expired rituximab), and highlighted a possible universal pathway for changes in HOS stability that occurred as a function of time. These data further revealed additional downstream unfolding differences in stability, notably
trastuzumab was shown to exhibit a spike in SDS at 2.25 keV consistent with the unfolding transition between intermediate 1 and 2. Given an SDS difference threshold of ±100, changes in the unfolding transition between intermediates 1 and 2 were observed in all but the expired rituximab sample. These data therefore revealed that, while the most prevalent change in stability may be argued to exist between the native state and initial unfolding intermediate, the SDS approach is capable of monitoring more subtle localized changes in biotherapeutic stability across the entirety of the unfolding study.

Importantly, our data highlighted that the structural stability of ‘x’ increased over time at the expense of both the native conformation and proceeding unfolding intermediate (intermediate 1, Figure 2). The increased stability of ‘x’ was further observed in tandem with the reduced lifetime of the native-

Figure 2. Comparison of collisionally unfolded mAbs before and after incubation at the ICH-stipulated accelerated aging conditions. Control CIU (a) data revealed three dominant unfolding populations (1, 2 and 3) in addition to the native-like conformation (N) for all mAbs studied. Samples subjected to accelerated aging (b) exhibit a similar unfolding profile, with an additional unfolding population (x) observed between the native and previously initial unfolding population (1). Difference plot analysis (c) highlights the extent of the unfolding differences between samples. Plotting the scaled deviation scores (SDS) (d) revealed characteristic spikes consistent with the appearance of a structural unfolding population denoted as ‘x.’ Despite minimal observable changes in the difference plot for the expired rituximab, the SDS plot highlights the consequences of accelerated aging on the sample.
like fold under CIU conditions (Figure 2). Taken together, these observations are attributed to the thermal stability decrease of the biotherapeutics tested over time. The reduced thermal stability of the native conformation may indicate an increased risk of protein misfolding that may in turn act as a pathway to subsequent protein aggregation. Furthermore, the existence of such misfolded species could further increase the inherent risk of immunogenic responses, either directly or through an downstream subvisible aggregate formation.

Hydrogen-deuterium exchange mass spectrometry of biotherapeutics subjected to accelerated storage conditions

While CIU-IM-MS is capable of detecting storage-dependent changes in thermal stability, we were interested in confirming the impact of these conditions on the HOS of mAbs studied using an in-solution labelling approach. HDX-MS was therefore chosen for these studies among all available in-solution labelling approaches, including covalent labelling and fast photochemical oxidation of proteins, due to both the commercial availability of suitable hardware and well-established methodology. HDX-MS measures mass shifts associated with labile hydrogen-deuterium exchange events as a function of time to determine localized changes in analyte HOS relative to a reference. Areas of increased or lower relative deuterium uptake are indicative of changes in HOS, which reflect the reduced or enhanced protection, respectively, of labile hydrogens in a manner highly correlated with solvent exposure.

Sequence coverage, replicable across all conditions studied, for the respective mAbs were as follows: bevacizumab 86.7% HC/59.8% LC; trastuzumab 89.3% HC/86.4% LC; NISTmAb RM8671 79.1% HC/53.1% LC; and rituximab 84.2% HC/98.1% LC. Coverage maps are shown in SI Figure 3. Regions of poor mAb sequence coverage were primarily located within the $V_L$ domain (bevacizumab and NISTmAb RM8671), the inter-chain disulfide bond dense stretch of the heavy chain hinge region and the C-terminal flanking constant (C2) domain that contains the conserved mAb N-linked glycosylation site. Regions of poor sequence coverage represent the limit of the method, as differences in comparator HOS will not be detected in these areas by this technique.

Data comparing the fractional and relative deuterium uptake for control samples, as well as those subjected to accelerated aging, are presented in Figure 3. The same data for samples subjected to storage at the manufacturer-recommended conditions are included with SI Figure 4. These data demonstrated an important trend among the majority of samples studied: while sporadic, differences (>±1 Da relative difference) in deuterium uptake were observed across the length of the mAb, the majority of these changes were clustered within the Fab structural domains ($V_{H}$, $V_{L}$, $C_1$, and $C_L$). These observations were further supported by the mirrored changes in deuterium uptake between the $C_1$ domain of the mAb heavy chain and $C_L$ of the adjacent light chain. These results are consistent with those performed by Zhang and co-workers, who reported that the most significant changes in deuterium uptake for a bevacizumab sample subjected to thermal stress (3 minutes at 65 or 70°C) were
located within the N-terminal Fab domain. Compared to our data, the changes in deuterium uptake observed by Zhang and co-workers occurred over a broader region of the Fab domain, including both the variable \((V_{iH}/V_{i})\) and constant domains \((C_{i}/C_{i})\). While differences in relative deuterium uptake were observed in both the heavy and light chain of the N-terminal variable domain \((V_{iH}/V_{i})\) of our dataset, the differences existing between the dataset here and of Zhang and co-workers are considered to be due to differences in the incubation conditions used. Taken together, these changes highlight potential pharmacodynamic concerns, given the requirement of the Fab domain for in situ antigen binding efficacy. Compared to all other samples studied here, the NISTmAb presented smaller changes in relative deuterium uptake. The observed differences were also more sporadic, and located across the length of both the heavy and light chains. These differences are attributed to its greater thermal stability as observed by CIU-IM-MS (Figure 2).

**Reverse phase accurate mass analysis of biotherapeutics subjected to accelerated storage conditions**

To examine if any changes occurred in the modifications, or if any proteolytic cleavages occurred after the ICH-recommended 6-month accelerated storage period, intact mAbs were analyzed by RP-LC-MS. This approach uses minimal sample handling, combined with a shortened reverse-phase chromatography step to permit the rapid intact mass analysis of all biotherapeutic glycoforms, and protein fragments. This approach was chosen because the glycated profile has been shown to impact immunotolerance, while proteolytic fragments represent previously reported age-dependent impurities.

Intact RP-LC-MS data comparing the fractional abundance of all species observed are presented in Figure 4. As a function of time, accounting for replicate error, no changes in the glycoform distributions were observed. When comparing the expired and unexpired lots of rituximab both before and after the accelerated storage conditions, we were able to identify differences in the high fractional abundance galactose-containing glycans. While these observations are potentially indicative of the effects of sample aging, we cannot confirm these conclusions given the absence of prior data supporting the glycan distribution of the mAb sample set. Considering that several degrees of freedom are exhibited by mAbs both in solution and the gas phase, these results are not surprising given that any minor changes in structure would be readily masked by this inherent structural flexibility. These results are consistent with previous reports presented by Tian and co-workers, where IgG subtypes (IgG1, IgG2, IgG3, and IgG4) were observed to be structurally indistinguishable by IM-MS despite observed differences in the structure of intact mAbs. The observed differences in CIU were attributed to differences in the respective disulfide bonding patterns of the IgG subtypes, with the extent and pattern of disulfide bonds imparting varying degrees of conformational stability. Based on these critical data, we speculate here that the observed differences in CIU between biotherapeutics subjected to unfolding at 0 and 6 months (Figure 2) may be indicative of disulfide bond rearrangements occurring over the stated time period. Supporting these considerations, data presented by Paborji and co-workers identified an increased risk of disulfide bond breakage occurring within a mAb incubated at higher temperatures. Additional reports further support the conclusion that these breakages, along with any sequential bond formation, can affect the stability of mAbs. However, given the absence of any disulfide mapping approach in our study, such as those previously reported in the literature, we cannot conclusively support our hypothesis using CIU-IM-MS data alone.
Complementing our CIU-IM-MS stability analysis, our HDX-IM-MS data revealed the impact of accelerated aging on the HOS of our chosen biotherapeutics. These HDX-IM-MS data indicate that the most notable changes in deuterium uptake occur within the Fab domain (Figure 3). Similarly, Zhang and co-workers reported the most significant changes in deuterium uptake for a bevacizumab sample subjected to thermal stress were located within the N-terminal Fab.

Figure 4. Reverse phase intact accurate mass analysis of mAbs before and after incubation at the ICH-stipulated accelerated aging conditions. Data highlight the fractional abundance of all observed glycoforms for bevacizumab (a), trastuzumab (b), NISTmAb (c) and both expired and in-date lots of rituximab (d). Masses consistent with a non-biologically relevant 2:2 ratio of heavy chain (HC) and light chain (LC) are denoted proceeding the glycan identification. * denotes one series of a heavy chain clipped variants, observed only in bevacizumab, with the site of the proteolytic cleavage highlighted. Error bars presented are representative of 2x the standard deviation. The glycan nomenclature is consistent with that commonly used to describe immunoglobulin glycoforms. Measured masses, including PPM mass errors for all data, are presented in the supplementary information (SI Table 26).
domain. In their work, the authors were further able to show that the observed changes in deuterium exchange were due to localized unfolding events, which were correlated with increased non-native aggregate states observed by complementary methods, and revealed potential sample-related safety or efficacy concerns.

Using intact RP-LC-MS accurate mass analysis, no changes in protein modifications with a fractional abundance above 0.5% were observed. These observations are important given the known effects of modifications, including denaturation, on the thermal stability of proteins. However, given the overall mass complexity of these biotherapeutics, more subtle changes in intact mass may be masked, and would be better characterized using methods that are capable of separations based on charge (e.g., ion exchange chromatography or microfluidic capillary electrophoresis). Alternatively, or in combination with the above separation techniques, steps could be made to reduce the mass complexity of the analyte using limited or complete proteolysis with middle-down and bottom-up proteomics approaches.

While no new protein modifications were observed, we were able to identify proteolytic degradation products for bevacizumab. These proteolytic degradation products, centered within the heavy chain V₁/C₁ inter-domain region, are supportive of a ‘proteolytic hot-spot’ which is consistent with previously published data. These proteolytic fragments are of concern when discussing the QA of a biotherapeutic, given the consequences of such proteolysis events on the structure of the antigen binding domain.

Based on our data and the methods used herein, we argue here that the most predominant accelerated aging-dependent QA changes can be attributed to changes in the HOS of the Fab domain (Figure 3). These changes in HOS can in turn be correlated with the reduced thermal stability of the native mAb conformation, preceding the formation of an increased stability unfolding population that we have identified here as ‘x’ (Figure 2). Furthermore, our RP-LC-MS studies have revealed a potential hot-spot for proteolysis between the V₁ and C₁ domains of the bevacizumab Fab domain (Figure 4). Taken together these data highlight potential pharmacodynamics and pharmacokinetics issues given the importance of the Fab domain and HOS stability on the efficacy of these biotherapeutic products.

While the observed changes in HOS and stability appear ubiquitous between the biotherapeutics studied, notable differences between CIU-IM-MS and HDX-MS data are observed when these are compared side by side. Comparing the impact of the accelerated storage conditions used, bevacizumab revealed the most notable change in unfolding, with population ‘x’ exhibiting an increased gas phase lifetime as a function of activation energy (~625 eV) compared to the remaining samples studied (~315 eV) (Figure 2). While trastuzumab has a point-of-use concentration (21 mg/ml) and non-ionic detergent (0.1 mg/ml Polysorbate 20) profile comparable to bevacizumab (25 mg/ml, 0.4 mg/ml Polysorbate 20), the former is supplied and stored as a lyophilized product prior to the point of use reconstitution. Under carefully controlled conditions, and given suitably low residual moisture content (<0.5%), lyophilization is known to be capable of increasing storage stability.

Based on the above considerations, the observed thermal stability differences between the native state of bevacizumab and all other samples studied may be represented by one or both of the following sample dependent variables: 1) formulation dependent effects, including the impact of the non-ionic detergent used and application of lyophilization to increase the long-term storage stability prior to the point of use (Table 1); and 2) sequence-dependent effects (Table 2), likely localized within the variable domains given an average similarity of 61 ± 15% compared to >98% across the remaining sequence.

In conclusion, our investigation of a series of commercial therapeutic products importantly highlights the consequences of biotherapeutic accelerated storage on the HOS and thermal stability. These data further reveal the capability of native IM-MS, CIU-IM-MS and HDX-IM-MS to examine these differences. Future work is needed to identify the consequences of product formulation differences, notably the effect of detergent concentration, to enable us to more conclusively determine the cause and effect relationships that we observed. These future studies would benefit from the expansion of analysis approaches to include both disulfide bond mapping, and a suitable charge variant analysis approach in lieu of the RP-LC-MS approach used here. Additional considerations for experimental methods that provide aggregate level information, including size-exclusion chromatography and subvisible particle analysis approaches, would provide valuable data on the downstream effects of these changes in HOS and stability.

Materials and methods

Five different mAb lots, across four different products, were chosen for this study. Products selected were the NIST reference material RM8671 (NISTmAb), and three commercially available mAb products from the same manufacturer (Genentech, San Francisco, CA): bevacizumab (Lot# 3049679), trastuzumab (Lot# 3049782), and two separate lots of rituximab (Lot# 461034 and 3031077). Excluding trastuzumab, all samples were supplied as liquid formulations for storage at 2–8°C. Trastuzumab was supplied as a lyophilized product, for storage at 2–8°C, which was reconstituted per manufacturer guidelines at the start of the studies. Additional details regarding product formulations, including concentrations, are provided in Table 1. With the exception of one lot of rituximab (Lot#: 461034, expiration date: July 2014) chosen as a negative control, all therapeutic mAbs were used within one month of their expiration date by the end of the study (August 2017).

According to ICH guidelines Q1A and Q5C, samples were aliquoted undiluted into 2 ml amber borosilicate HPLC vials (Agilent, Santa Clara, CA) to mimic the final product packing material used by the manufacturer. Vials were capped using lids having a PTFE insert, and purged with nitrogen. Four separate vials of each mAb were incubated at the ICH-specified accelerated storage conditions for refrigerated products, 25 ± 2°C and 60 ± 5% RH, for the specified minimum of 6 months, in the absence of light using a TPS (New Columbia, PA) C-EVO temperature/humidity test.
Additional triplicate tests were performed on separate samples, incubated under the same ICH-specified conditions, at 1 and 3 months. Control samples, stored in the absence of light at the manufacturer-recommended storage conditions (2–8°C, ambient humidity), were tested in triplicate at 0 and 6 months. All samples were stored vertically to prevent interactions between the sample and the lid.

All IM-MS experiments, including CIU, were performed using a Waters (Milford, MA) Synapt G2-Si. IM-MS instrumental parameters were optimized to prevent unnecessary gas phase activation, consistent with previously published methods. Immediately prior to analysis, samples were buffered exchanged into 150 mM ammonium acetate (Fisher Chemical, A114) (pH 6.9) using Amicon Ultra centrifugal filters (EMD Millipore, Burlington, MA) with a 10 kDa cut-off and diluted to 5 µM using the same buffer for analysis. Samples were ionized using a nano-electrospray source operated in positive ion mode, using coated borosilicate capillaries (New Objective, Woburn, MA), with the source cone set at 40 V operating at a temperature of 30°C. Nitrogen traveling wave ion mobility collision cross section (TWCCS)N2 values were calculated as the average of each technical replicate acquired under 3 different ion-mobility parameter sets, using previously published methods.

CIU experiments were performed on the quadrupole selected +25 precursor ion, with the trap activation energy ramped from 20V to 120V in 2.5V increments. CIU fingerprint, difference plot and SDS scoring analysis were performed using an in-house MATLAB (MathWorks, Natick, MA) script adapted from the CIUSuite analysis package originally written in the Python coding language. Data were imported into MATLAB using datasets normalized in Microsoft Excel (Redmond, WA), with minimal smoothing applied using MassLynx (Waters, Milford, MA). Data presented are the averaged technical replicates for all samples studied.

All HDX-MS experiments were performed using a Waters (Milford, MA) Synapt G2-Si coupled to a Waters ACQUITY UPLC M-Class with hydrogen-deuterium exchange technology. Deuterated samples (3 µg) were quenched at 0, 10 seconds, 1, 10, 60 or 240 minutes, before injection onto the UPLC and digested online using a Waters Enzyme Pepsin column (20°C) prior to trapping on a Waters Vanguard C18 trap column (0.5°C). The digested samples were then chromatographically separated using a Waters 1 × 100 mm ACQUITY UPLC Protein BEH C4 column, eluting with a 13-minute water/acetonitrile (0.1% formic acid) gradient (20–60% acetonitrile) at a flow rate of 0.15 ml/minute. The column was re-equilibrated by first holding at 95% acetonitrile for 2 minutes, then dropping to 5% acetonitrile for another minute. Eluted samples were subsequently ionized using an electrospray ionization source operating in positive ion mode, with the in-source fragmentation set to 20V, operating at ion transfer tube and vaporizer temperatures of 400 and 200°C, respectively. All mass spectra were acquired using the Orbitrap at a resolution of 15000. Output data were deconvoluted using the Auto ReSpect algorithm within Protein Deconvolution 3.0 (Thermo Fisher Scientific), prior to additional processing and averaging in Microsoft Excel. Protein sequences for all samples, except trastuzumab, were taken from drugbank.ca. Trastuzumab sequence data were taken from work published by Beck and co-workers, consistent with heavy chain sequence differences. Common sequence modifications assumed for all mAbs studied included C-terminal lysine cleavages and N-terminal glutamines to pyroglutamine conversion, where relevant.

Sample selection

This study was designed with several considerations regarding the samples selected. First, all samples selected were IgG1 type antibodies. Second, consistent with ICH recommendations regarding the use of suitable reference materials to support method evaluation, these studies were expanded to include the NISTmAb. Third, as we were interested in comparing the effect of thermal stability as a function of accelerated aging on in-date samples, an unopened negative control was included for study against an unexpired sample from the same manufacturer: rituximab lot 1 (Lot# 3031077) expiration August 2017, rituximab lot 2 (Lot# 461034) expiration July 2014 (study ended August 2017). In addition, to evaluate the effect of concentration on sample ageing, we chose the biotherapeutic bevacizumab, formulated as a 25 mg/ml solution compared to the 10 mg/ml for both rituximab and the NISTmAb. Last, to compare the effect of lyophilization on long-term product stability, we additionally investigated trastuzumab, which was supplied as a commercial lyophilized product, with a shelf life of 1 month past the reconstitution date at a concentration of 25 mg/ml.
CHO Chinese Hamster Ovary
CIU Collision Induced Unfolding
HC Heavy Chain
HDX-MS Hydrogen-Deuterium Exchange-Mass Spectrometry
HOS Higher Order Structure
ICH International Council for Harmonisation
IM-MS Ion Mobility-Mass Spectrometry
LC Light Chain
mAb Monoclonal antibody
QA Quality Attribute
RH Relative Humidity
RMSD Root-Mean-Square Deviation
RP-LC-MS Reverse Phase-Liquid Chromatography-Mass Spectrometry
SDS Scaled Deviation Score
TWCNSS Travelling Wave Collision Cross Section measured in Nitrogen
21 mg/ml. All other formulation differences, and brand names, are given in Table 1.

Abbreviations

Acknowledgments

This project was supported in part by an appointment to the Research Participation Program at the Center for Drug Evaluation and Research administered by the Oak Ridge Institute for Science and Engineering and the U.S. Food and Drug Administration for R.A.K. The authors would further like to thank Brandon Ruotolo and Daniel Polasky from The University of Michigan for useful discussions regarding implementation of several CIUSuite features into MATLAB. This publication reflects the views of the authors and should not be construed to represent FDA’s views or policies.

ORCID

David A. Keire http://orcid.org/0000-0002-7767-7904

References

1. Tsong Y. Recent issues in stability study. J Biopharm Stat. 2003;13(3):vii–ix. doi:10.1081/BIP-120022753.
2. ICH Harmonised Tripartite Guideline: Pharmaceutical Development Q8(R2). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2009.
3. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27:26. doi:10.1038/nbt1099-26.
4. Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, e al. Structure, heterogeneity and developability assessment of therapeutic antibodies. mAbs. 2019;11(2):239–64.
5. Ambrogelli A, Gozo S, Katiyar A, Dellatore S, Kune Y, Bhat R, Sun J, Li N, Wang D, Nowak C, et al. Analytical comparability study of recombinant monoclonal antibody therapeutics. mAbs. 2018;10(4):513–38. doi:10.1089/mabs.2018.1438797.
6. Leblanc Y, Bihoreau N, Jube M, Andre MH, Tellier Z, Chevreux G. Glycation of polyclonal IgGs: effect of sugar excipients during stability studies. Eur J Pharm Biopharm. 2016;102:185–90. doi:10.1016/j.ejpb.2016.03.016.
7. Agarkhed M, O’Dell C, Hsieh M-C, Zhang J, Goldstein J, Srivastava A. Effect of polysorbate 80 concentration on thermal and photostability of a monoclonal antibody. AAPS PharmSciTech. 2013;14(1):1–9. doi:10.1208/s12249-012-9878-0.
8. Vlask J, Ionescu R. Fragmentation of monoclonal antibodies. mAbs. 2011;3:253–63.
9. Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25(12):1325–34. doi:10.1093/glycob/cwv065.
10. Fang J, Richardson J, Du Z, Zhang Z. Effect of Fc–Glycan structure on the conformational stability of IgG revealed by hydrogen/deuterium exchange and limited proteolysis. Biochemistry. 2016;55(6):860–68. doi:10.1021/acs.biochem.5b01323.
11. Lam XM, Yang JY, Cleland JL. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci. 1997;86(11):1250–55. doi:10.1016/s09794135.
12. Haywood J, Mozicinacci O, Allegre KM, Kerwin BA, Schöneich C. Light-induced conversion of Trp to gty and gty hydroperoxide in IgG1. Mol Pharm. 2013;10(3):1146–50. doi:10.1021/mp300680c.
13. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22:1393. doi:10.1038/nbt0126.
14. Goetze AM, Schau MR, Flynn GC. Assessing monoclonal antibody product quality attribute criticality through clinical studies. mAbs. 2010;2:500–07.
15. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr Pharm Biotechnol. 2002;3:349–60.
16. Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, Narhi LO, Topp EM. Immunogenicity of therapeutic protein aggregates. J Pharm Sci. 2016;105(2):417–30. doi:10.1016/j.xphs.2015.11.002.
17. Maa Y-F, Hsu CC. Investigation on fouling mechanisms for recombinant human growth hormone sterile filtration. J Pharm Sci. 1998;87(7):808–12. doi:10.1016/s980114x.
18. Maa Y-F, Hsu CC. Protein denaturation by combined effect of shear and air-liquid interface. Biotechnol Bioeng. 1997;54(6):503–12. doi:10.1002/(SICI)1097-0290(19970620)54:6<503::AID-BIT1>3.0.CO;2-N.
19. Passot S, Fonseca F, Barbouche N, Marin M, Alarcon-Lorca M, Rolland D, Rpaud M. Effect of product temperature during primary drying on the long-term stability of lyophilized proteins. Pharm Dev Technol. 2007;12(6):543–53. doi:10.1080/10837450701563459.
20. Eckhardt BM, Oeswein JQ, Bewley TA. Effect of freezing on aggregation of human growth hormone. Pharm Res. 1995;12:1360–64.
21. Cao E, Chen Y, Cui Z, Foster PR. Effect of freezing and thawing rates on denaturation of proteins in aqueous solutions. Biotechnol Bioeng. 2003;82(6):684–90. doi:10.1002/bit.10612.
22. Porter D, Vollrath F. The role of kinetics of water and amide bonding in protein stability. Soft Matter. 2008;4(2):328–36. doi:10.1039/B713972A.
23. ICH Harmonised Tripartite Guideline: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products Q5C. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 1995.
24. Nowak CK, Cheung JM, Dellatore S, Katiyar A, Bhat R, Sun J, Ponniah G, Neill A, Mason B, Beck A, et al. Forced degradation of recombinant monoclonal antibodies: A practical guide. mAbs. 2017;9(8):1217–30. doi:10.1080/19420862.2017.1368602.
25. Krishnan S, Pallito MM, Ricci MS. Development of formulations for therapeutic monoclonal antibodies and Fc fusion proteins. In: Jameel F, Hershenson S, editors. Formulation and process developement strategies for manufacturing biopharmaceuticals. Hakoben (NJ): John Wiley & Sons, Inc.; 2010. p. 383–427.
26. Singh SM, Bandi S, Jones DNM, Mallela KMG. Effect of polysorbate 20 and polysorbate 80 on the higher-order structure of a monoclonal antibody and its fab and Fc fragments probed using
60. Redman EA, Batz NG, Mellors JS, Ramsey JM. Integrated microfluidic capillary electrophoresis-electrospray ionization devices with online MS detection for the separation and characterization of intact monoclonal antibody variants. Anal Chem. 2015;87(4):2264–72. doi:10.1021/ac503964j.

61. Sandin S, Överstedt L-G, Wikström A-C, Wrangle Ö, Skoglund U. Structure and flexibility of individual immunoglobulin G molecules in solution. Structure. 2004;12(3):409–15. doi:10.1016/j.str.2004.02.011.

62. Zhang X, Zhang L, Tong H, Peng B, Rames MJ, Zhang S, Ren G. 3D structural fluctuation of IgG1 antibody revealed by individual particle electron tomography. Sci Rep. 2015;5:9803. doi:10.1038/srep09803.

63. Tian Y, Han L, Buckner AC, Ruotolo BT. Collision induced unfolding of intact antibodies: rapid characterization of disulfide bonding patterns, glycosylation, and structures. Anal Chem. 2015;87(22):11509–15. doi:10.1021acs.analchem.5b03291.

64. Pahorji M, Pochopin NL, Copolla WP, Bogardus JB. Chemical and physical stability of chimeric L6, a mouse–human monoclonal antibody. Pharm Res. 1994;11:764–71.

65. Lacy ER, Baker M, Brigham-Burke M. Free sulphydryl measurement as an indicator of antibody stability. Anal Biochem. 2008;382(1):66–68. doi:10.1016/j.ab.2007.07.016.

66. Moritz B, Stracke JO. Assessment of disulfide and hinge modifications in monoclonal antibodies. Electrophoresis. 2017;38(6):769–85. doi:10.1002/elps.201600425.

67. Trivedi MV, Laurence JS, Siahaan TJ. The role of thiols and disulfides in protein chemical and physical stability. Mol Cell Proteomics. 2009;10(6):1716–25. doi:10.2174/138920309789630534.

68. Lakbub JC, Shipman JT, Desaire H. 2017. Recent mass spectrometry-based techniques and considerations for disulfide bond characterization in proteins. Analytical and bioanalytical chemistry.

69. Houde D, Peng Y, Berkowitz SA, Engen JR. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics. 2010;9(8):1716–28. doi:10.1074/mcp.M900540-MCP200.

70. Mo J, Yan Q, So CK, Soden T, Lewis MJ, Hu P. Understanding the impact of methionine oxidation on the biological functions of IgG1 antibodies using hydrogen/deuterium exchange mass spectrometry. Anal Chem. 2016;88(19):9495–502. doi:10.1021/acs.analchem.6b01958.

71. Belov AM, Zang L, Sebastiano R, Santos MR, Bush DR, Karger BL, Ivanov AR. Complementary middle-down and intact monoclonal antibody proteoform characterization by capillary zone electrophoresis – mass spectrometry. Electrophoresis. 2018;39(16):2069–82. doi:10.1002/elps.201800067.

72. Said N, Gahoulal R, Kuhn L, Beck A, François Y-N, Leize-Wagner E. Structural characterization of antibody drug conjugate by a combination of intact, middle-up and bottom-up techniques using sheathless capillary electrophoresis – tandem mass spectrometry as nanoESI infusion platform and separation method. Anal Chim Acta. 2016;918:50–59. doi:10.1016/j.aca.2016.03.006.

73. Tang X, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res. 2004;21:191–200.

74. Goyon A, Fekete S, Beck A, Veuthey J-L, Guilarmore D. Unraveling the mysteries of modern size exclusion chromatography - the way to achieve confident characterization of therapeutic proteins. J Chromatogr B. 2018;1092:368–78. doi:10.1016/j.jchromb.2018.06.029.

75. Narhi LO, Corvari V, Ripple DC, Afonina N, Cecchini I, Defelippis MR, Garidel P, Herre A, Koulov AV, Lubiniecki T, et al. Subvisible (2–100 μm) particle analysis during biopharmaceutical drug product development: part 1, considerations and strategy. J Pharm Sci. 2015;104(6):1899–908. doi:10.1002/jps.24437.

76. ICH Hamonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2003.

77. Bush MF, Hall Z, Giles K, Hoyes J, Robinson CV, Ruotolo BT. Collision cross sections of proteins and their complexes: a calibration framework and database for gas-phase structural biology. Anal Chem. 2018;90(22):9557–65. doi:10.1021/acs.analchem.8b02953.

78. Houde D, Engen JR. Conformational analysis of recombinant monoclonal antibodies with hydrogen/deuterium exchange mass spectrometry. In: Beck A, editor. Glycosylation engineering of biopharmaceuticals: methods and protocols. Totowa (NJ): Humana Press; 2013. p. 269–89.

79. Shihaiva PV, Bond NJ, Gatto L, Lilley KS. Effects of traveling wave ion mobility separation on data independent acquisition in proteomics studies. J Proteome Res. 2013;12(6):2323–39. doi:10.1021/pr300775k.

80. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34(suppl_1):D668–D72. doi:10.1093/nar/gkj067.

81. Beck A, Debaene F, Diemer H, Wagner-Rousset E, Colas O, Dorselaer AV, Gianferani S. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies. J Mass Spectrom. 2015;50(2):285–97. doi:10.1002/jms.3554.

82. Lewis DA, Guzzetta AW, Hancock WS, Costello M. Characterization of humanized anti-TAC, an antibody directed against the interleukin 2 receptor, using electrospray ionization mass spectrometry by direct infusion, LC/MS, and MS/MS. Anal Chem. 1994;66:585–95.

83. Werner WE, Wu S, Mulkerrin M. The removal of pyroglutamic acid from monoclonal antibodies without denaturation of the protein chains. Anal Biochem. 2005;342(1):120–25. doi:10.1016/j.ab.2005.04.012.

84. ICH Harmonised Tripartite Guideline: Specifications; Test Procedures and Acceptance Criteria for Biotechnological/Biological Products Q6B. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 1999.